Beam Therapeutics

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Beam Therapeutics excels in base editing therapies, poised for growth

Beam Therapeutics showcased strong performance in trials and technology development, positioning itself as a leader in base editing therapies.
While facing challenges in clinical translation and regulatory landscapes, Beam's focus on innovative solutions presents growth opportunities in gene editing.
Overall, Beam's financial strength, promising data, and strategic vision offer a solid foundation for future success in the biotech industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that on Friday, July 29, 2022, the company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) that the BEAM-201 Investigational New Drug (IND) application for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T cell lymphoblastic lymphoma (T-LL) has been placed on clinical hold. BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T cell (CAR-T) development candidate. The BEAM-201 IND was submitted at the end of June. The FDA indicated they will provide an official clinical hold letter to Beam within 30 days. Beam plans to provide additional updates pending discussion with the FDA.

Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application

BMO Capital Markets has raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $61 from $41, with a Market Perform rating unchanged. The model changes include updated collaboration revenues for Verve Therapeutics Inc's (NASDAQ: VERV) VERVE-101.

Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage

ARK Innovation ETF

Cathie Wood's ARK Innovation ETF is one of the most controversial and followed ETFs. What if you cherry-picked her best ideas.

Beam In On The ARKK Buffet

The recent 4-year partnership between Pfizer and Beam Therapeutics involves $300 million upfront to speed validation of the technology and an additional $1.05 billion in milestone payments. A recent amended agreement between Verve Therapeutics and Beam Therapeutics is a target swap that will give Beam access to Verve's validated GalNAc-lipid nanoparticle-mediated (LNP) delivery technology.

Revisiting Beam Therapeutics Among Collaborative Catalysts

Adaptive Biotechnologies

Novavax

Vertex Pharmaceuticals

Check these health care stocks out for your watchlist right now

Top Health Care Stocks To Buy Right Now? 4 To Watch

Editas Medicine

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. The post The 3 Leaders of the Gene Editing Revolution appeared first on InvestorPlace.

The 3 Leaders of the Gene Editing Revolution

Biogen

CRISPR Therapeutics

Intellia Therapeutics

Regeneron Pharmaceuticals

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on InvestorPlace.

7 Moonshot Investments Upending a $10 Trillion Industry

AMC Entertainment

These two stocks could generate life-changing gains for patient shareholders.

Have $1,000 to Invest? 2 Stocks to Buy Right Now That Could Help Make You a Fortune

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new research highlighting the company's internal efforts to develop improved transplant conditioning regimens for patients with sickle cell disease (SCD) undergoing hematopoietic stem cell transplantation (HSCT) will be presented today, June 27, 2022, at 4:00 p.m. CEST at the Federation of American Societies for Experimental Biology (FASEB) Genome Engineering Conference by Nicole Gaudelli, Ph.D., director, head of gene editing at Beam. The conference is being held from June 26-30, 2022, in Lisbon, Portugal.

Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant

Beam Therapeutics Inc. (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ: BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established.

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success

Blink Charging

ChargePoint Holdings

EVgo

Tesla

Wallbox NV

Stocks tied broadly to the electric vehicle charging industry, as listed today by Seeking Alpha, are shown by their Market-Maker-valued price range limits on 6/8/22 close prices. No comment necessary.

EV Industry Reward-Risk Map

Exact Sciences

Teladoc

Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.

5 Health Care Stocks Cathie Wood Favors

Recursion Pharmaceuticals

10X Genomics

Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.

3 Cathie Wood Stocks That Could Deliver Monster Returns

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2022 Jefferies Healthcare Conference on Friday, June 10, 2022 at 9:30 a.m. ET in NYC.

Beam Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 8.18% and 89.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates

BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022

Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new preclinical data from several programs across its base editing portfolio at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting. The meeting is being held May 16-19, 2022, in Washington, DC.

Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual Meeting

BioNTech SE

Arcus Biosciences

Vir Biotechnology

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.

4 Undervalued Biotech Stocks to Add to Your Buy List

CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, and Giuseppe Ciaramella, Ph.D., president and chief scientific officer, will participate in a fireside chat during the virtual Guggenheim Genomic Medicines and Rare Disease Conference on Friday, April 1, 2022 at 9:00 a.m. ET.

Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president and chief scientific officer, will participate in a fireside chat during the Barclays 2022 Global Healthcare Conference on Tuesday, March 15, 2022 at 8:30 a.m. ET. The conference will be held in Miami, FL from March 15-17, 2022.

Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference

Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion

Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET.

Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

News for Beam Therapeutics Stock (BEAM)